Fundraising FoxSR One Capital Management — 2023 Investments
4 investments dated 2023 · listed companies and verified rows first · show all
Addex Therapeutics is a clinical-stage pharmaceutical company that develops orally available small molecule drugs known as allosteric modulators for neurological disorders.
BiotechHealthtechGeneva
Roger Mills(Executive Officer, Director)inMikhail Kalinichev(Executive Officer)inJean-Philippe Rocher(Executive Officer)inRobert Lutjens(Executive Officer)inTimothy Dyer(Executive Officer, Director)Vincent Lawton(Director)
Board seatJake Nunn· per SEC Form D · $3.7M raise · filed Apr 2023
Co-investorsNew Enterprise Associates (NEA)Sofinnova PartnersACORN BIOVENTURES
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.
BiotechHealthtech
Lyn Baranowski(CEO)in
Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalInVivium CapitalNorwest Venture PartnersPivotal Life Sciences+9 more
46 Capital is an investment firm focused on early-stage companies across multiple sectors, led by experienced professionals with backgrounds in venture capital, private equity, healthcare, energy, and finance.
Fintech
Tim Clark(Managing Director)
Co-investorsHurricane VenturesAndreessen HorowitzAscenta CapitalAvaana CapitalBoxGroupClaypond Capital+7 more
Nimbus Therapeutics is a biotechnology company that designs precision small molecule medicines using a computational, multidisciplinary drug discovery approach.
AI & Machine LearningBiotechDeep TechHealthtech
Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesDementia Discovery FundGV (Google Ventures)Lightstone Ventures+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.